Arete Wealth Advisors’s Matinas BioPharma MTNB Stock Holding History

Arete Wealth Advisors’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-600	Closed	-$32K	–	419
2021 Q1	$32K	Hold	600	–	–	﹤0.01%	415
2020 Q4	$52K	Hold	600	–	–	0.01%	400
2020 Q3	$23K	Hold	600	–	–	﹤0.01%	379
2020 Q2	$23K	Hold	600	–	–	﹤0.01%	368
2020 Q1	$18K	Hold	600	–	–	﹤0.01%	339
2019 Q4	$68K	Buy	+600	New	+$34.8K	0.01%	385

Other funds holding MTNB

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

CCM

Courage Capital Management Nashville, Tennessee $70.6M AUM 13.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Arete Wealth Advisors's MTNB Position: Q2 2021 in Review

Arete Wealth Advisors sold out of Matinas BioPharma (MTNB) in Q2 2021, closing a stake of 600 shares — an estimated $32K sold.

Arete Wealth Advisors first reported a position in MTNB in Q4 2019 and held it in 6 quarters. The position peaked at $68K in Q4 2019. 67 funds tracked by Wall St. Rank hold MTNB as of Q2 2021.

Arete Wealth Advisors reported no remaining Matinas BioPharma position as of Q2 2021 after selling out during the quarter.
Arete Wealth Advisors sold 600 Matinas BioPharma shares in Q2 2021, an estimated $32K.
Arete Wealth Advisors first reported a position in Matinas BioPharma in Q4 2019 and held it in 6 quarters.
Arete Wealth Advisors's Matinas BioPharma position peaked at $68K in Q4 2019.
67 funds tracked by Wall St. Rank held Matinas BioPharma as of Q2 2021.

Based on Arete Wealth Advisors's 13F filing for Q2 2021, filed 9 Aug 2021.